Detection of carriers in the Ashkenazi Jewish Population: An objective comparison of high-throughput genotyping versus gene-by-gene testing

Susan D. Klugman, Nicole Schreiber-Agus, Shivani Nazareth, Eric A. Evans

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: High-throughput genotyping allows rapid identification of targeted mutations at a fraction of the cost of current gene-by-gene testing methodologies. An objective comparison of the two methodologies allows providers to assess the clinical validity/utility of high-throughput carrier screening and establish a comfort level with new genomic technologies. Aim: To verify that high-throughput genotyping accurately determines patient carrier status, DNA samples from previously identified carriers (n=31) of Ashkenazi Jewish genetic diseases were anonymized and submitted for retesting by high-throughput genotyping. Results: The results were 100% concordant (95% CI: 0.998-1), demonstrating that high-throughput genotyping assays accurately identify carriers of targeted mutations in the Ashkenazi Jewish population. In addition, carrier status for diseases and mutations not previously tested was uncovered using the high-throughput assay. Conclusions: High-throughput genotyping is a cost-effective and clinically valid approach to carrier screening. The use of a broader screen for Ashkenazi Jewish individuals increases the detection of carriers in this population.

Original languageEnglish (US)
Pages (from-to)763-767
Number of pages5
JournalGenetic Testing and Molecular Biomarkers
Volume17
Issue number10
DOIs
StatePublished - Oct 1 2013

Fingerprint

Mutation
Population
Genes
Costs and Cost Analysis
Inborn Genetic Diseases
Technology
DNA

ASJC Scopus subject areas

  • Genetics(clinical)

Cite this

Detection of carriers in the Ashkenazi Jewish Population : An objective comparison of high-throughput genotyping versus gene-by-gene testing. / Klugman, Susan D.; Schreiber-Agus, Nicole; Nazareth, Shivani; Evans, Eric A.

In: Genetic Testing and Molecular Biomarkers, Vol. 17, No. 10, 01.10.2013, p. 763-767.

Research output: Contribution to journalArticle

@article{b9070e4483dc485e8c8b9e3828e1b9f9,
title = "Detection of carriers in the Ashkenazi Jewish Population: An objective comparison of high-throughput genotyping versus gene-by-gene testing",
abstract = "Background: High-throughput genotyping allows rapid identification of targeted mutations at a fraction of the cost of current gene-by-gene testing methodologies. An objective comparison of the two methodologies allows providers to assess the clinical validity/utility of high-throughput carrier screening and establish a comfort level with new genomic technologies. Aim: To verify that high-throughput genotyping accurately determines patient carrier status, DNA samples from previously identified carriers (n=31) of Ashkenazi Jewish genetic diseases were anonymized and submitted for retesting by high-throughput genotyping. Results: The results were 100{\%} concordant (95{\%} CI: 0.998-1), demonstrating that high-throughput genotyping assays accurately identify carriers of targeted mutations in the Ashkenazi Jewish population. In addition, carrier status for diseases and mutations not previously tested was uncovered using the high-throughput assay. Conclusions: High-throughput genotyping is a cost-effective and clinically valid approach to carrier screening. The use of a broader screen for Ashkenazi Jewish individuals increases the detection of carriers in this population.",
author = "Klugman, {Susan D.} and Nicole Schreiber-Agus and Shivani Nazareth and Evans, {Eric A.}",
year = "2013",
month = "10",
day = "1",
doi = "10.1089/gtmb.2013.0105",
language = "English (US)",
volume = "17",
pages = "763--767",
journal = "Genetic Testing and Molecular Biomarkers",
issn = "1945-0265",
publisher = "Mary Ann Liebert Inc.",
number = "10",

}

TY - JOUR

T1 - Detection of carriers in the Ashkenazi Jewish Population

T2 - An objective comparison of high-throughput genotyping versus gene-by-gene testing

AU - Klugman, Susan D.

AU - Schreiber-Agus, Nicole

AU - Nazareth, Shivani

AU - Evans, Eric A.

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Background: High-throughput genotyping allows rapid identification of targeted mutations at a fraction of the cost of current gene-by-gene testing methodologies. An objective comparison of the two methodologies allows providers to assess the clinical validity/utility of high-throughput carrier screening and establish a comfort level with new genomic technologies. Aim: To verify that high-throughput genotyping accurately determines patient carrier status, DNA samples from previously identified carriers (n=31) of Ashkenazi Jewish genetic diseases were anonymized and submitted for retesting by high-throughput genotyping. Results: The results were 100% concordant (95% CI: 0.998-1), demonstrating that high-throughput genotyping assays accurately identify carriers of targeted mutations in the Ashkenazi Jewish population. In addition, carrier status for diseases and mutations not previously tested was uncovered using the high-throughput assay. Conclusions: High-throughput genotyping is a cost-effective and clinically valid approach to carrier screening. The use of a broader screen for Ashkenazi Jewish individuals increases the detection of carriers in this population.

AB - Background: High-throughput genotyping allows rapid identification of targeted mutations at a fraction of the cost of current gene-by-gene testing methodologies. An objective comparison of the two methodologies allows providers to assess the clinical validity/utility of high-throughput carrier screening and establish a comfort level with new genomic technologies. Aim: To verify that high-throughput genotyping accurately determines patient carrier status, DNA samples from previously identified carriers (n=31) of Ashkenazi Jewish genetic diseases were anonymized and submitted for retesting by high-throughput genotyping. Results: The results were 100% concordant (95% CI: 0.998-1), demonstrating that high-throughput genotyping assays accurately identify carriers of targeted mutations in the Ashkenazi Jewish population. In addition, carrier status for diseases and mutations not previously tested was uncovered using the high-throughput assay. Conclusions: High-throughput genotyping is a cost-effective and clinically valid approach to carrier screening. The use of a broader screen for Ashkenazi Jewish individuals increases the detection of carriers in this population.

UR - http://www.scopus.com/inward/record.url?scp=84884560832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884560832&partnerID=8YFLogxK

U2 - 10.1089/gtmb.2013.0105

DO - 10.1089/gtmb.2013.0105

M3 - Article

C2 - 23952016

AN - SCOPUS:84884560832

VL - 17

SP - 763

EP - 767

JO - Genetic Testing and Molecular Biomarkers

JF - Genetic Testing and Molecular Biomarkers

SN - 1945-0265

IS - 10

ER -